BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...Micromet AG to the U.S. in 2006. Pieris...
BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

...the boards of Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Pieris...
BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...a 2017 immuno-oncology deal Servier did with Pieris...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...hired Ingmar Bruns as CMO. Bruns, who succeeds Yaping Shou, was SVP and head of clinical development at Pieris...
BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...VP and head of clinical development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Reine was CFO at Pieris...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...cell therapies. A February 2018 deal with Pieris Pharmaceuticals Inc. gave Seattle Genetics access to Pieris’...
...platform to develop bispecific candidates to treat solid tumors and blood cancers. The deal combines Pieris’...
...AG (Xetra:BAYN), Leverkusen, Germany bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. ISA Pharmaceuticals B.V., Leiden, Netherlands Pieris...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...Development and Manufacturing Scott Lauder to chief technology officer. Knopf was SVP and CBO at Pieris...
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...bispecific compounds that target 4-1BB on T cells and a protein on tumor cell surfaces. Pieris...
...Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE: PFE), New York, N.Y. Pieris...
...plc Bristol-Myers Squibb Co. Elpiscience Biopharmaceuticals Co. Ltd. Enumeral Biomedical Holdings Inc. Harvard Medical School Inhibrx LLC Merck & Co. Inc. Pfizer Inc. Pieris...
BioCentury | Feb 23, 2018
Financial News

Pieris raises $50.6M in follow-on

...Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares...
...$9.45 on Feb 13, before the offering was proposed. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Shannon Lehnbeuter Pieris...
BioCentury | Feb 16, 2018
Company News

Seattle Genetics, Pieris partner for immuno-oncology

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Allison Johnson Pieris...
Items per page:
1 - 10 of 114
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...Micromet AG to the U.S. in 2006. Pieris...
BioCentury | Feb 20, 2021
Politics, Policy & Law

Creating access to cancer drugs in Africa

...the boards of Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Pieris...
BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...a 2017 immuno-oncology deal Servier did with Pieris...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...hired Ingmar Bruns as CMO. Bruns, who succeeds Yaping Shou, was SVP and head of clinical development at Pieris...
BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...VP and head of clinical development at Agios Pharmaceuticals Inc. (NASDAQ:AGIO). Reine was CFO at Pieris...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...cell therapies. A February 2018 deal with Pieris Pharmaceuticals Inc. gave Seattle Genetics access to Pieris’...
...platform to develop bispecific candidates to treat solid tumors and blood cancers. The deal combines Pieris’...
...AG (Xetra:BAYN), Leverkusen, Germany bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. ISA Pharmaceuticals B.V., Leiden, Netherlands Pieris...
BioCentury | May 30, 2018
Company News

Management tracks: Zafgen, Rigel

...Development and Manufacturing Scott Lauder to chief technology officer. Knopf was SVP and CBO at Pieris...
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

...bispecific compounds that target 4-1BB on T cells and a protein on tumor cell surfaces. Pieris...
...Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE: PFE), New York, N.Y. Pieris...
...plc Bristol-Myers Squibb Co. Elpiscience Biopharmaceuticals Co. Ltd. Enumeral Biomedical Holdings Inc. Harvard Medical School Inhibrx LLC Merck & Co. Inc. Pfizer Inc. Pieris...
BioCentury | Feb 23, 2018
Financial News

Pieris raises $50.6M in follow-on

...Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares...
...$9.45 on Feb 13, before the offering was proposed. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Shannon Lehnbeuter Pieris...
BioCentury | Feb 16, 2018
Company News

Seattle Genetics, Pieris partner for immuno-oncology

...Antibody-drug conjugate company Seattle Genetics Inc. (NASDAQ:SGEN) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) partnered to develop bispecific...
...bispecific candidates to treat solid tumors and blood cancers. The partners will develop candidates using Pieris'...
...Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Allison Johnson Pieris...
Items per page:
1 - 10 of 114